IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness

J Immunol. 2001 Jun 15;166(12):7504-13. doi: 10.4049/jimmunol.166.12.7504.

Abstract

Endotoxin tolerance, the transient, secondary down-regulation of a subset of endotoxin-driven responses after exposure to bacterial products, is thought to be an adaptive response providing protection from pathological hyperactivation of the innate immune system during bacterial infection. However, although protecting from the development of sepsis, endotoxin tolerance also can lead to fatal blunting of immunological responses to subsequent infections in survivors of septic shock. Despite considerable experimental effort aimed at characterizing the molecular mechanisms responsible for a variety of endotoxin tolerance-related phenomena, no consensus has been achieved yet. IL-12 is a macrophage- and dendritic cell (DC)-derived cytokine that plays a key role in pathological responses to endotoxin as well as in the induction of protective responses to pathogens. It recently has been shown that IL-12 production is suppressed in endotoxin tolerance, providing a likely partial mechanism for the increased risk of secondary infections in sepsis survivors. We examined the development of IL-12 suppression during endotoxin tolerance in mice. Decreased IL-12 production in vivo is clearly multifactorial, involving both loss of CD11c(high) DCs as well as alterations in the responsiveness of macrophages and remaining splenic DCs. We find no demonstrable mechanistic role for B or T lymphocytes, the soluble mediators IL-10, TNF-alpha, IFN-alphabeta, or nitric oxide, or the NF-kappaB family members p50, p52, or RelB.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Apoptosis / immunology
  • B-Lymphocytes / immunology
  • Dendritic Cells / cytology
  • Dendritic Cells / immunology*
  • Dendritic Cells / metabolism
  • Dose-Response Relationship, Immunologic
  • Down-Regulation / immunology
  • Female
  • Immune Tolerance* / genetics
  • Immunization, Secondary
  • Injections, Intraperitoneal
  • Integrin alphaXbeta2 / biosynthesis
  • Interferon Type I / deficiency
  • Interferon Type I / genetics
  • Interleukin-10 / deficiency
  • Interleukin-10 / genetics
  • Interleukin-12 / antagonists & inhibitors*
  • Interleukin-12 / biosynthesis*
  • Lipopolysaccharides / administration & dosage*
  • Lipopolysaccharides / immunology*
  • Macrophages, Peritoneal / immunology*
  • Macrophages, Peritoneal / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Nude
  • NF-kappa B / deficiency
  • NF-kappa B / genetics
  • NF-kappa B p50 Subunit
  • Nitric Oxide / deficiency
  • Nitric Oxide / genetics
  • Proto-Oncogene Proteins / deficiency
  • Proto-Oncogene Proteins / genetics
  • Spleen / cytology
  • Spleen / immunology
  • T-Lymphocytes / immunology
  • Transcription Factor RelB
  • Transcription Factors / deficiency
  • Transcription Factors / genetics
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / deficiency
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Integrin alphaXbeta2
  • Interferon Type I
  • Lipopolysaccharides
  • NF-kappa B
  • NF-kappa B p50 Subunit
  • Proto-Oncogene Proteins
  • Relb protein, mouse
  • Transcription Factors
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Transcription Factor RelB
  • Interleukin-12
  • Nitric Oxide